Table 3.
Patient ID | Changes between initial diagnosis and recurrence | Post recurrence survival [months] | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
PSMA-positive vessels | CD34-positive vessels | PSMA/CD34ratios | PSMA-positive non-endothelial cells | |||||||
amount | score | amount | score | amount | score | intensity | amount | IRS | ||
1 | -32% | ↔ | -65% | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | 22.2 |
2 | -71% | ↔ | -19% | ↑ | ↓ | ↓ | ↑ | ↔ | ↑ | 35.3 |
3 | +63% | ↑ | -28% | ↑ | ↑ | ↔ | ↓ | ↔ | ↓ | 7.5 |
4 | -99% | ↓ | -92% | ↓ | ↓ | ↔ | ↔ | ↑ | ↑ | 5.6 |
5 | -27% | ↔ | -86% | ↔ | ↑ | ↔ | ↔ | ↔ | ↔ | 8.7 |
6 | +125% | ↑ | +193% | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | 32.4 |
7 | -50% | ↓ | -65% | ↔ | ↓ | ↓ | ↑ | ↑ | ↑ | 12.7 |
8 | -99% | ↔ | -91% | ↓ | ↓ | ↑ | ↓ | ↑ | ↔ | 63.5 |
9 | -51% | ↓ | n. a. | ↓ | n. a. | ↓ | ↑ | ↔ | ↑ | 18.4 |
10 | +36% | ↑ | -32% | ↑ | ↑ | ↔ | ↔ | ↑ | ↑ | 12.0 |
11 | -91% | ↓ | -49% | ↔ | ↓ | ↓ | ↔ | ↑ | ↑ | 26.8 |
12 | -100% | ↓ | -67% | ↔ | ↓ | ↓ | ↓ | ↓ | ↓ | 28.3 |
13 | +329% | ↑ | +218% | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | 3.4 |
14 | -31% | ↔ | -71% | ↓ | ↑ | ↓ | ↑ | ↑ | ↑ | 32.7 |
15 | -92% | ↓ | -71% | ↓ | ↓ | ↓ | ↑ | ↔ | ↑ | 4.5 |
16 | -10% | ↔ | +47% | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | 18.5 |
↔, stable; ↑, increase; ↓, decrease; IRS, immunoreactive score; n. a., not available (excluded due to unspecific CD34 staining).